Reach Us +44-1647-403003
Active Specific Immunotherapy (ASI) in Cancer Treatment: Five Case Reports | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Active Specific Immunotherapy (ASI) in Cancer Treatment: Five Case Reports

Roni Moya1,3, Mike KS Chan1,2,3, Michelle BF Wong1,3, Dmitry Klokol2,3, Yvonne Cashinn Chia2,3 and Shing Yi Pan2,3*
1Fetal Cell Technologies International, (FCTI ) EU & Asia-Pacific, Malaysia
2Baden Research and Testing Lab, Asia-Pacific, Malaysia
3European Wellness Academy, Germany
*Corresponding Author: Shing Yi Pan, Academic Board Advisor and Program Facilitator, European Wellness Academy, Klosterstraße 205, 67480 Edenkoben, Germany, Tel: +60143708083, Email: [email protected]

Received Date: Jul 27, 2019 / Accepted Date: Sep 09, 2019 / Published Date: Sep 16, 2019

Citation: Moya R, Chan MKS, Wong MBF, Klokol D, Chia YC, et al. (2019) Active Specific Immunotherapy (ASI) in Cancer Treatment: Five Case Reports. J Cancer Sci Ther 11: 256-259DOI: 1948-5956

Copyright: © 2019 Moya R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Immunotherapy, including the complementary immunotherapy for cancer, can be categorized as either specific or nonspecific, both with the aim to enhance the immunity against tumors. A proper immunotherapy approach must address a patient’s individual features of complexity such as tumor’s immune suppressive and pro-inflammatory aspects, antigen heterogeneity and immunogenicity. The Active Specific Immunotherapy (ASI) is capable of rearming and boosting the immune system against cancer by exclusively regulating patient’s own immune-modulatory molecules. This article presents five distinct clinical reports of cancer patients that have undergone the ASI treatment, combined with ozone therapy, vitamins infusion and several programs of chemotherapies. As a result, the ASI improved the immune status of all patients and their overall life quality by reducing pain, fatigue and infections recurrences. Furthermore, the ASI treatment did not cause any negative side effects nor interfere whatsoever with the chemotherapy protocol. In conclusion, although further studies are urgently required in the field, ASI offers an interesting and safe strategy as integrative personalized immunotherapy.